Qbrexza is owned and commercialized by Journey Medical Corporation, which acquired the exclusive U.S. and international rights to the topical medication portfolio. Originally developed and brought through regulatory approvals by Dermira, the asset transitioned under corporate acquisitions to Eli Lilly and subsequently to Journey Medical Corporation, which manages its ongoing marketing, physician outreach, and commercial distribution for patients suffering from primary axillary hyperhidrosis.